Kornimate/medical-research-clean huggingface dataset:
vascular improvement with olmesartan medoxomil study

Conditions: Hypertension

Summary: the purpose of this study is to compare in patients with primary hypertension, the non-blood pressure lowering effects of one-year therapy with olmesartan medoxomil vs. those of atenolol on changes in the vascular structure and function.


Eligibility criteria:
inclusion criteria: * male or female * 18-75 years of age * mean seated diastolic bp 90-109 or mean seated systolic bp of 140-179 exclusion criteria: * secondary hypertension * renal disease * diabetes mellitus * serum creatinine \>3.0 mg/dl * hemoglobin \<10 mg/dl (males) or \<9mg/dl (females) * wbc count \<2000 cells/ml * platelet count \<100,000 cells/ml * either alt \& ast \>2.5 x upper limit of normal * bmi \>35 kg/m2 * tia or cerebrovascular attack within 3 months of study entry
clinical and radiographic outcomes of cad/cam vs conventionally constructed occlusal splints in patients with temporomandibular joint disorders

Conditions: Temporomandibular Disorder

Summary: the aim of this study is to compare between digitally formed occlusal splints versus conventional occlusal splints in patients with tmds regarding patient satisfaction


Eligibility criteria:
inclusion criteria: - patients' age ranging from 20 to 50 years. tmds according to the research diagnostic criteria (rdc) for tmd (rdc/tmd) and magnetic resonance imaging (mri) for confirmation which include: i. painful tmj audible and palpable click. ii. no functional mouth limitation. iii. tmj tenderness. fully dentate patients without any malocclusion and good oral hygiene. co-operative patient that should show motivation to follow up. exclusion criteria: * patients with systemic diseases which could affect tmj, e.g., rheumatoid arthritis, osteoarthrosis, myasthenia gravis and fibromyalgia. * patients showing bony irregularities e.g. osteophyte as recorded by magnetic resonance imaging. * patients taking analgesic, muscle relaxant, or anti-inflammatory drugs were excluded because such drugs could influence the results. * any condition that contra-indicates mri such as patients with pacemakers in heart. * patients with removable dental prosthesis
research on nutritional risk indexes and inflammatory indicators in postoperative complications and prognosis of epithelial ovarian cancer patients

Conditions: Epithelial Ovarian Cancer

Summary: the goal of this observational study is to explore the influence and predictive significance of nutritional risk indicators and inflammatory indicators on postoperative complications and prognosis of patients with epithelial ovarian cancer (eoc). the main question it aims to answer is: can preoperative nutritional risk and inflammatory indexes predict postoperative complications? do preoperative nutritional risk and inflammatory indexes better predict the prognosis of patients with epithelial ovarian cancer? which index is the best predictor of postoperative complications or prognosis for patients?


Eligibility criteria:
inclusion criteria: 1. histologically confirmed primary epithelial ovarian, peritoneal, and fallopian tube cancers. 2. patients received comprehensive staged surgery or debulking surgery. 3. available data of laboratory examination within 7 days before the surgery. exclusion criteria: 1. borderline ovarian tumor. 2. receipt of neoadjuvant chemotherapy. 3. presence of other conditions influencing laboratory data, like hepatitis, kidney disease, autoimmune diseases, infectious diseases, blood disease, etc. 4. concurrent cancer in other organs. 5. absence of surgery or biopsy only. 6. multiple staged surgeries.
lessons on urethral lidocaine in urodynamics

Conditions: Urethra Issue; Pelvic Organ Prolapse; Urinary Incontinence; Vaginal Vault Prolapse; Cystocele; Uterine Prolapse; Vaginal Prolapse; Pelvic Floor Disorders

Summary: this trial will assess whether use of intraurethral 2% lidocaine jelly meaningfully impacts sensation during filling (i.e., a change of more than 25% of first sensation, first desire to void, strong desire to void, or maximum cystometric capacity) and determine whether the use of intraurethral 2% lidocaine jelly meaningfully impacts pain/discomfort, filling metrics, and voiding metrics.

this trial is a randomized, double blind, controlled trial for patients undergoing complex cystometric evaluation. patients will undergo routine complex cystometric evaluation for acquisition of baseline data using a small amount of intraurethral aqueous jelly for catheter lubrication. then, they will be randomized to instillation of either placebo (additional intraurethral aqueous jelly, 5ml) or intraurethral 2% lidocaine jelly. participants then undergo complex cystometry a second time. normal variations in studies with placebo will be compared to variations within the 2% lidocaine jelly group to determine if cystometric parameters are altered in any clinically important ways. patient discomfort will also be evaluated by both the patient and the urodynamics advanced practice nurse.

Eligibility criteria:
inclusion criteria: * female patients * \>18 years of age * already scheduled (or being scheduled) for uds to assess urinary incontinence * able to speak and read in english exclusion criteria: * diagnosis of pelvic pain, interstitial cystitis, or bladder pain syndrome * known neurogenic disease impacting voiding/ continence (e.g., parkinson disease, multiple sclerosis, myasthenia gravis, recent stroke) * active uti * pelvic organ prolapse that is unable to be easily reduced * pregnancy or breastfeeding * allergy or hypersensitivity to lidocaine or local anesthetics
home inotropic therapy in children

Conditions: Congenital Disorders

Summary: inotropic therapy is a well-established practice for children with advanced congestive heart failure (chf). inotropes are intravenous medications to help the heart pump stronger and prolong life while awaiting heart transplantation. traditionally children have been maintained on inotropic therapy in the hospital under close, monitored supervision. the united network for organ sharing (unos), which governs organ distribution, has now changed listing criteria allowing patients awaiting heart transplantation to be discharged to home, yet maintaining a higher status on the waiting list. in adults, home inotropic therapy has been shown to be a safe and cost-effective bridge to transplantation. to date, there are no data on the use of home inotropic therapy in children. hypothesis: we request to do a retrospective chart review of patients receiving this therapy to determine safety and efficacy of continuous ambulatory home inotropic therapy in children.

hypothesis: we request to do a retrospective chart review of patients receiving this therapy to determine safety and efficacy of continuous ambulatory home inotropic therapy in children. methods: data will be obtained from choa and coram home healthcare, inc over a two year period, january 1, 2004 through december 31, 2005. data will be collected on approximately 35 children aged 0-18 years receiving therapy. the length of therapy, type of therapy, therapy-related complications, number of readmissions, deaths at home and catheter-related infections data will be collected. inclusion criteria: receiving inotropic support at home choa patients with coram healthcare only

Eligibility criteria:
inclusion criteria: * receiving inotropic support at home * choa patients with coram healthcare only * medical charts between 2.2.2004 and 12.31.2005 exclusion criteria: * those who do not meet inclusion criteria

Keywords: pediatric congestive heart failure inotropes
endovenous lidocaine and serum cytokines concentration

Conditions: Cholelithiasis

Summary: ineffective treatment of postoperative pain may cause organic damage and chronic pain. nevertheless, opioids, the leading drugs used for this purpose, present side effects that sometimes restrict their usability. in a multimodal context, new postoperative analgesia techniques have been developed focusing in the reduction of opioid use and their adverse effects, as well as postoperative chronic pain prevention. in this background, continuous intravenous infusion of lidocaine during perioperative period has shown to be promising. this trial aimed to compare postoperative analgesia, opioid consumption, duration of ileus and length of hospital stay and il-1, il-6, il-10, α tnf and γ ifn levels in patients undergoing to laparoscopic cholecystectomies who received intravenous lidocaine in comparison to a control group. intravenous lidocaine in the perioperative period of laparoscopic cholecystectomies was not able to reduce postoperative pain, opioid consumption, and duration of ileus or length of hospital stay. however, its anti-inflammatory effect was evidenced by the significant changes in the studied cytokines.

forty-four patients undergoing laparoscopic cholecystectomy, under general anesthesia, were randomly allocated in two groups. the first group received intravenous lidocaine infusion during the procedure until one hour postoperatively; meanwhile the second group received intravenous saline for the same period of time. the intervention was double-blind. in the postoperative period, both groups received dipyrone and morphine pca. pain was assessed by visual numeric scale (vns) at rest and when coughing at 1st, 2nd, 4th, 12th e 24th hour after the end of the surgery. blood samples for cytokines measurement were taken at the end of procedure and 24 hours later. the total morphine pca demand, the time for the first flatus and the length of hospital stay were also recorded and compared.

Eligibility criteria:
inclusion criteria: * age over 18 years and * physical status according to the american society of anesthesiologists (asa) i and ii exclusion criteria: * patients older than 75 years, * patients with heart disease, * patients with history of: * kidney failure, * liver failure, * psychiatric disorder, * chronic use of opioids or medications that could cause induction of liver enzymes (anticonvulsants). * the presentation of adverse effects during the intervention or postoperative complications, and the conversion to open surgery.

Keywords: cholelithiasis cytokines under general anesthesia
prediction of delayed cerebral ischemia after subarachnoid hemorrhage using dynamic 18f-fdg pet/ct

Conditions: Aneurysmal Subarachnoid Haemorrhage

Summary: a pilot trial for assessing early microvascular alterations after aneurysmal subarachnoid hemorrhage using dynamic 18f-fdg pet/ct. the primary endpoint will be the measure of early changes in cerebral glucose uptake reflecting microperfusion.

we hypothesize that an early irreversible microvascular deterioration following initial bleeding could contribute to dci occurrence. more precisely, we suspect that dci areas are somehow overlaps of regions in which microperfusion is precociously altered, shortening circulatory reserves, and territories of secondarily spasmed arteries further lowering blood flow, resulting in ischemia. we aim to explore the potential microvasculature alteration through cerebral glucose perfusion and metabolism assessment using early dynamic 18f-fluorodesoxyglucose positron emission tomography/computer tomography (dynamic 18f-fdg pet/ct). if our hypothesis turned out to be valid, we would at the same time be able to determine risk factors for this unpredictable complication and gain remarkable insight into dci pathophysiology. thus, the purpose of this trial is to demonstrate, in patients affected by sah, the correlation between early cerebral glucose uptake defects in 18f-fdg pet/ct and delayed cerebral infarction in magnetic resonance imaging (mri).

Eligibility criteria:
inclusion criteria: * written informed consent to participate in the study must be obtained from the subject or proxy/legal representative prior to enrollment. * males and females aged 18 years and older. * sah proven by computed tomography (ct) and that has occurred within the last 72 hours. * ruptured saccular aneurysm angiographically confirmed by digital subtraction angiogram or ct angiogram, which has been successfully secured by surgical clipping or endovascular coiling. * high-risk subjects for dci: "thick clot" on the hospital admission ct (grade 3 or grade 4 on the modified fisher scale). * a woman of childbearing potential is eligible only if the serum pregnancy test performed during the screening period is negative. exclusion criteria: * pet/ct contradications * mri contradications * gadolinium or meglumine hypersensitivity * glomerular filtration rate \<30ml/min * sah due to other causes than ruptured saccular aneurysm. * post-hsa cardiac arrest. * high sustained icp ( \>20mmhg lasting \>20min) despite optimal treatment. * significant and concomitant organ failure amongst the following: hypotension with systolic blood pressure \<90mmhg refractory to treatment; unresolved pulmonary edema or pneumonia with severe hypoxia defined as pao2/fio2 \<150; severe cardiac failure requiring inotropic support. * patients with "do-not-resuscitate" orders, withdrawal of care situation, dying patient. * vulnerable patient populations (minor, legal vulnerability, prisoner) * pregnant and nursing mothers.

Keywords: aneurysmal subarachnoid haemorrhage delayed cerebral ischemia positron emission tomography cerebral microcirculation
type distribution of human papillomavirus in adult african women diagnosed with invasive cervical cancer

Conditions: Infections, Papillomavirus; Cervical Cancer

Summary: the aim of the study is to assess the distribution of the most frequent types of human papillomavirus in african women diagnosed with invasive cervical cancer.


Eligibility criteria:
inclusion criteria: * a female aged 21 years or more, presenting with a lesion macroscopically suggestive of invasive cervical cancer. * scheduled for cervical biopsy as per routine procedure at the participating institution on the day of the visit or on a later date. * written or oral-witnessed informed consent obtained from the subject prior to any study procedure. * no prior chemo- or radiotherapy for cervical cancer. exclusion criteria: not applicable

Keywords: human papillomavirus
a study of lanadelumab (takhzyro) and icatibant (firazyr®) in persons with hae in china

Conditions: Hereditary Angioedema (HAE)

Summary: the chinese health authority has approved lanadelumab to prevent hereditary angioedema (hae) attacks in persons of 12 years and older. it has also approved icatibant to treat acute hae attacks in persons 2 years and older. one of the main aims of this study is to learn about the number of hae attacks in 1 month in chinese persons with hae during their treatment with lanadelumab. the other main aim is to learn how much time is needed to resolve acute hae attacks when treated with icatibant. other aims of this study are to learn more about side effects of lanadelumab and icatibant treatment as well as to collect additional information on the treatment with lanadelumab, such as the dose and how often it needs to be given, reasons for stopping the treatment with lanadelumab and how long it was taken until stopping. participants will be treated by their doctors according to routine medical practice. only data already available in the medical records of the participants will be reviewed and collected during this study.


Eligibility criteria:
inclusion criteria: * chinese participants who have received at least one dose of lanadelumab or icatibant from the lanadelumab nmpa approval date (02-dec-2020) to the date of the day before the 1st site initiation date. * informed consent will be obtained from the participant (and/or a legally authorized representative) prior to including that participant as a study participant and accessing that participant's data, except for cases in which the informed consent can be waived by the site. exclusion criteria: • participation in other interventional studies involving lanadelumab, icatibant, or any other hae drug or investigational product on or after the date of the participant's lanadelumab or icatibant initiation.
nineteen years of modified cimt in a clinical setting, to improve arm and hand function after stroke

Conditions: Stroke; Neurological Diseases or Conditions

Summary: the goal of this observational study is to determine if clinically constraint-induced movement therapy (cimt), when applied in a routine clinical practice, can improve arm- and hand function after stroke. additionally, the study seeks to identify which patients experienced the greatest improvements, and to examine factors that contribute to the long-term sustainability of the treatment. stroke is one leading cause of disability, often resulting in difficulties using the arm and hand function on one side, making daily activities challenging. cimt aims to enhance arm and hand function after stroke by incorporating intensive training and restraining the non-affected limb, thereby encouraging the use of the affected arm and hand. while numerous studies have demonstrated the effectiveness of cimt, and it is recommended in national clinical guidelines, it is rarely implemented in clinical practice due to challenges in execution and sustainability. moreover, it remains unclear which patients benefit the most from the treatment. at a rehabilitation clinic in sweden, cimt has been incorporated into routine care for 19 years, which is uncommon. participants undergo cimt as outpatients over a three-week period, with one patient being treated at a time. by retrospectively observe outcomes from this clinically implemented and sustained model of cimt, the study aims to address the following questions: * is cimt, when conducted in a regular clinical setting, effective? * are there relationships between patient characteristics and outcomes?


Eligibility criteria:
inclusion criteria: * post-acute injury (participants had completed primary rehabilitation and were living at home) * reduced ability to use the hemi-paretic arm * ability to actively extend the metacarpophalangeal and the interphalangeal joints 10° * ability to actively extend the wrist 20° exclusion criteria: * unable to walk and balance safely without using the non-affected hand, with or without a mobility aid * unable to understand the content of the training or lack of motivation * serious cognitive deficit or instable medical condition believed to affect training participation * pain in the affected arm believed to affect training intensity

Keywords: stroke rehabilitation physiotherapy occupational therapy neurological rehabilitation upper extremity cimt ci therapy
vitamin d level in recurrent pv

Conditions: Recurrent Pityriasis Versicolor

Summary: serum samples will be taken from patients with recurrent pityriasis versicolor for the evaluation of vitamin d level.


Eligibility criteria:
inclusion criteria: * - patients with recurrent pityriasis versicolor (active now) and not taking treatment for it. * patients of both genders. * age ≥18 years old. exclusion criteria: * - patients with other cutaneous diseases. * patient's having dandruff (scaly scalp) even if not symptomatizing. * pregnant and lactating females, children, prisoners, cognitively impaired or mentally disabled subjects. * patients with autoimmune diseases. * patients with immunodeficiency diseases. * immunosuppressed patients e.g. hiv, diabetics, organ transplant, malignancy, patients taking immunosuppressive drugs e.g. chemotherapy, cortisone.
study of vadastuximab talirine (sgn-cd33a; 33a) in combination with azacitidine in patients with previously untreated higher risk mds

Conditions: Myelodysplastic Syndrome

Summary: this is a phase 1/2 study to evaluate the combination of vadastuximab talirine (sgn-cd33a; 33a) and azacitidine in subjects with previously untreated international prognostic scoring system (ipss) intermediate-2 or high risk myelodysplastic syndrome (mds).

in the phase 1 portion of the study, escalating doses of 33a will be evaluated in combination with azacitidine, and a dose of 33a will be selected to proceed to phase 2. the phase 2 portion of the study is randomized, double-blind and placebo-controlled; it is designed to compare the overall response rate (orr) between 2 study arms.

Eligibility criteria:
inclusion criteria: * subjects with cytologically/histologically confirmed mds according to the world health organization (who) 2008 classification. * previously untreated for myelodysplastic syndrome (mds) * age ≥18 years of age. * eligible for therapy with azacitidine. * life expectancy of at least 12 weeks. * eastern cooperative oncology group (ecog) performance status ≤2. * adequate baseline laboratory parameters. exclusion criteria: * received prior treatment for mds with lenalidomide or hypomethylating agents (hmas). * history of one of the following myeloproliferative neoplasms: essential thrombocythemia, polycythemia vera, and primary myelofibrosis. * second malignancy currently requiring active therapy (except for hormonal/anti-hormonal treatment, eg, prostate or breast cancer). * candidates for allogeneic stem cell transplant at the time of screening.

Keywords: antibody-drug conjugate cd33 antigen
an observational study of the safety of mabthera/rituxan (rituximab) in participants with granulomatosis with polyangiitis (wegener's) or microscopic polyangiitis

Conditions: Granulomatosis With Polyangiitis; Microscopic Polyangiitis

Summary: this prospective observational study will evaluate the long-term safety of mabthera/rituxan (rituximab) in participants with granulomatosis with polyangiitis (wegener's) or microscopic polyangiitis. data will be collected for a maximum of 4 years from participants initiated on mabthera/rituxan therapy by their physician according to prescribing information.


Eligibility criteria:
inclusion criteria: * adult participants, \>/= 18 years of age * granulomatosis with polyangiitis (gpa) or microscopic polyangiitis (mpa), according to chapel hill consensus conference definitions for mpa and american college of rheumatology (acr) criteria for the classification of gpa * disease severity requiring rituximab treatment per the investigator's assessment exclusion criteria: * prior use of rituximab (except if received within 4 weeks of screening) * known hypersensitivity to rituximab, to any component of the product, or to murine proteins * pregnant or breastfeeding women * diagnosis of churg-strauss syndrome
conservative versus aggressive revascularization in patients with intermediate lesions undergoing percutaneous coronary intervention with angiography guidance alone

Conditions: Coronary Artery Disease

Summary: the aim of this study was to compare conservative versus aggressive strategy in patients with intermediate lesions with angiography guidance alone.

to investigate whether conservative revascularization using criteria of 70% diameter stenosis would be non-inferior to aggressive revascularization using criteria of 50% diameter stenosis in coronary intermediate lesions, we conducted the conservative revascularization versus aggressive revascularization for coronary stenting with everolimus-eluting stents (smart-case) trial.

Eligibility criteria:
inclusion criteria: * intermediate coronary lesion(s) (diameter stenosis between 50% and 70% by quantitative coronary analysis) * target lesion(s) must be located in a native coronary artery with diameter of ≥2.25 mm and ≤4.25 mm exclusion criteria: * cardiogenic shock * myocardial infarction (mi) within 48 hours * left main lesion * drug-eluting stent implantation in the target vessel prior to enrollment * ≥2 chronic total occlusions in major coronary territories * history of bleeding diathesis or known coagulopathy * gastrointestinal or genitourinary bleeding within 3 months or major surgery within 2 months * platelet count \<100,000 cells/mm3 * planned elective surgical procedure that would necessitate interruption of thienopyridine during the first 6 months after enrollment * non-cardiac co-morbid conditions with life expectancy \<1 year or that may result in protocol non-compliance (per site investigator's medical judgment).

Keywords: angioplasty, transluminal, percutaneous coronary everolimus-eluting stent